Bayer/€BAYN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Bayer
Bayer AG, operating under the ticker BAYN, is a global enterprise with core competencies in the life sciences fields of healthcare and agriculture. Founded in 1863, the company is headquartered in Leverkusen, Germany, and operates in several sectors, including Pharmaceuticals, Consumer Health, Crop Science, and Animal Health. Bayer is known for developing new molecules for use in innovative products and solutions to improve the health of humans, animals, and plants.
- Ticker
- €BAYN
- Sector
- Health
- Primary listing
- XETRA
- Employees
- 87,775
- Headquarters
- Leverkusen, Germany
- Website
- www.bayer.com
Bayer Metrics
BasicAdvanced
€55B
-
-€1.47
0.81
€0.11
0.20%
Price and volume
Market cap
€55B
Beta
0.81
52-week high
€53.86
52-week low
€25.78
Average daily volume
2.7M
Dividend rate
€0.11
Financial strength
Current ratio
1.347
Quick ratio
0.926
Long term debt to equity
1.167
Total debt to equity
1.344
Interest coverage (TTM)
4.06%
Profitability
EBITDA (TTM)
13,654
Gross margin (TTM)
59.35%
Net profit margin (TTM)
-3.16%
Operating margin (TTM)
16.53%
Effective tax rate (TTM)
-66.47%
Revenue per employee (TTM)
€520,000
Management effectiveness
Return on assets (TTM)
4.34%
Return on equity (TTM)
-4.56%
Valuation
Price to revenue (TTM)
1.185
Price to book
1.87
Price to tangible book (TTM)
-2.8
Price to free cash flow (TTM)
47.57
Free cash flow yield (TTM)
2.10%
Free cash flow per share (TTM)
1.16
Dividend yield (TTM)
0.20%
Forward dividend yield
0.20%
Growth
Revenue change (TTM)
-0.21%
Earnings per share change (TTM)
630.81%
3-year revenue growth (CAGR)
-1.42%
10-year revenue growth (CAGR)
2.04%
3-year earnings per share growth (CAGR)
-26.70%
10-year earnings per share growth (CAGR)
-12.61%
What the Analysts think about Bayer
Analyst ratings (Buy, Hold, Sell) for Bayer stock.
Analyst projections of the future price of Bayer stock.
Bulls say / Bears say
Third-quarter adjusted EBITDA rose 6.9%, with Pharmaceuticals sales up 8% as Nubeqa and Kerendia grew strongly. Bayer raised its 2026 earnings and cash-flow outlook, signalling that the new-drug growth is beginning to offset older-product declines. (Bayer)
China has approved asundexian, making it the first Factor XIa inhibitor authorised worldwide; Bayer says its trial reduced recurrent ischaemic stroke by 26% without increasing overall bleeding. Further approvals could open a new growth opportunity, though commercial uptake is not yet established. (Bayer, Reuters)
Crop Science has launched two of ten planned products expected to reach at least €500 million in peak annual sales each, and reported nearly €400 million of cost-reduction progress. These launches and efficiencies offer a route to improve the division’s longer-term growth and margins. (Reuters)
Despite raising its 2026 cash-flow forecast, Bayer still expects full-year free cash flow to be negative, and third-quarter free cash flow was also negative as legal-settlement payments weighed. The recent reduction in net debt was largely supported by a €3 billion Apollo payment, rather than operating cash generation alone. (Bayer)
Crop Science sales fell 2.4% on a currency- and portfolio-adjusted basis in the third quarter, while its adjusted EBITDA dropped 41.3%. Bayer cited regulatory effects, adverse weather and higher costs, showing that agricultural weakness could offset gains elsewhere in the group. (Bayer)
Data summarised monthly by Lightyear AI. Last updated on 3 Nov 2026.
Bayer Financial Performance
Revenues and expenses
Bayer Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Bayer
AllEURUSDGBP
Fund name | Fund size | €BAYN weighting |
|---|---|---|
iShares Edge MSCI Europe Value Factor€CEMS | €2.6B | 3.75% |
iShares Edge MSCI Europe Value Factor£IEFV | €2.6B | 3.75% |
iShares Dax ESG€EXIA | €127M | 3.53% |
iShares MSCI Europe Health Care Sector£ESIH | €890M | 3.10% |
iShares MSCI Europe Health Care Sector€ESIH | €890M | 3.10% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.